تست Immune Cells (IC)

For Atezolizumab therapy in urothelial carcinoma, Triple negative breast carcinoma and non small cell lung carcinoma as following:
   - Negative: <1%
   - IC1: 1-5%
   - IC2: 5-10%
   - IC3: >=10%